medical paternalism are the main arguments put forward by the proponents of direct-to-consumer advertising. These are summarised in a paper by the New Zealand Marketing Association which also contains an interesting appraisal of the current Australian situation. 1 Unfortunately, partial and unbalanced misinformation, which is the hallmark of New Zealand's direct-to-consumer advertising, is promotion clearly designed to drive choice rather than inform it.
Four years ago New Zealand general practitioners were abruptly awoken to the effectiveness of direct-to-consumer advertising. Overnight they had to cope with an unexpected and unwelcome increase in workload. Patients using the leading brand of beclomethasone appeared at surgeries in droves asking to switch to an orange inhaler (fluticasone), as a television advertisement had told them that their brown inhaler was to be withdrawn in a few weeks, to protect the ozone layer.
In the view of many prescribers, the television advertisements contained several inaccuracies and raised patient anxiety unnecessarily as neither patients nor many general practitioners realised that generic beclomethasone would continue to be available. A senior company official would later admit that the timing of this campaign was chosen for marketing rather than environmental reasons. In particular, a generic equivalent to the company's inhalers was in the wings.
Many general practitioners were incensed at being pressured to switch well-controlled patients to what they considered to be a drug with little or no added therapeutic benefit. 2 Perhaps more worrying, the longer-term health effects of a near doubling of average daily doses of inhaled steroids (many prescribers seemed unaware of the potency of fluticasone) are yet to be quantified.
There was also a significant increase in cost to the New Zealand taxpayer from the switch in prescribing driven by direct-to-consumer advertising. At the time, fluticasone carried a premium on the equivalent dose of beclomethasone. In addition, the increase in effective dose by many prescribers not making the 2:1 switch in dose increased this price differential and the overall subsided cost. The true cost will never be made public as there was a confidential, out-of-court settlement days before a Fair Trading Act case (initiated by the Pharmaceutical Management Agency of New Zealand to recover the costs to the health budget) was due to start in the High Court. consistently show that when a patient asks for a specific drug by name they receive it more often than not. 3, 4, 5 This occurs even when the prescribers report they would not have prescribed the drug had it not been requested. 3, 4 In 2002, the heads of three of the four Departments of General Practice wrote to general practitioners setting out their intention to lobby for a ban on direct-to-consumer advertising and asking for colleagues to share their experiences. Within days more than half of all the general practitioners in New Zealand responded.
The advertising and pharmaceutical industries were incensed and actively tried to discredit this advocacy. 2 Four out of five general practitioners writing back felt negatively about direct-toconsumer advertising. This feeling is reflected in the statements supporting a ban issued by all of the main New Zealand health professional bodies and a number of consumer groups. 3 The then Health Minister repeatedly stated a desire to heed this advice and to ban brand direct-to-consumer advertising. 6 The New Zealand cabinet supported exploring this through the trans-Tasman harmonisation process. Whether that promise can be fulfilled may now rest with yet another round of public consultations.
Even if brand advertising can be banned via the trans-Tasman agreement, both countries (and many others) will still be faced with the growing problem of regulating 'disease awareness' advertising which is seen by many as direct-to-consumer advertising by the back door. 7 The Australia-US Free Trade Agreement could be a step towards less regulation in Australia. The Australian Consumers' Association website lists some of the tricks used to circumvent the current Australian regulations, with several examples of back door direct-to-consumer advertising. 8 First, it is stated that gynaecomastia and breast pain still occur with eplerenone (as has been a major adverse effect of spironolactone). This is a somewhat disingenuous interpretation of the data as in fact no study has shown an excess of these events with eplerenone compared to placebo. As with any adverse effect, there is a spontaneous background event rate that is not further added to by eplerenone therapy.
Next, it is implied that because spironolactone reduces relative risk of death by 30% in patients with severe heart failure it is a more effective drug than eplerenone, that 'only' reduced risk of death by 15% in post-myocardial infarction (MI) heart failure patients. Again, making comparisons regarding the impact of therapies across trials is poor science and tells us nothing about the relative merits of individual drugs because of the differing disease states and background treatments in the differing trials.
Finally, and most importantly, it is stated that spironolactone is well known and inexpensive and 'thus unlikely to be superseded until more data about eplerenone are available'.
This statement clearly implies that the two drugs can be used interchangeably for the same clinical indication. Just as eplerenone should not be given to patients with severe heart failure (because it has not as yet been tested in such a patient population) the same is true of spironolactone
